Search

Your search keyword '"Sacco, Rodolfo"' showing total 406 results
Start Over Author "Sacco, Rodolfo" Publication Type Academic Journals
406 results on '"Sacco, Rodolfo"'

1. Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib

Author

Stefanini, Bernardo, Tovoli, Francesco, Trevisani, Franco, Marseglia, Mariarosaria, Di Costanzo, Giovan Giuseppe, Cabibbo, Giuseppe, Sacco, Rodolfo, Pellizzaro, Filippo, Pressiani, Tiziana, Chen, Rusi, Ponziani, Francesca Romana, Foschi, Francesco Giuseppe, Magini, Giulia, Granito, Alessandro, and Piscaglia, Fabio

Published
2024
Full Text
View/download PDF

2. Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab

Author

Rimini, Margherita, Montes, Margarida, Amadeo, Elisabeth, Vitiello, Francesco, Kudo, Masatoshi, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Lonardi, Sara, Finkelmeier, Fabian, Salani, Francesca, Antonuzzo, Lorenzo, Marra, Fabio, Iavarone, Massimo, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Sacco, Rodolfo, Rapposelli, Ilario Giovanni, Scartozzi, Mario, Nicoletta, Pella, Aldrighetti, Luca, Persano, Mara, Camera, Silvia, Rossari, Federico, Foti, Silvia, Kumada, Takashi, Hiraoka, Atsushi, Iwamoto, Hideki, Rizzato, Mario Domenico, Himmelsbach, Vera, Masi, Gianluca, Corradi, Mattia, Celsa, Ciro, Fabio, Conti, Frassineti, Giovanni Luca, Cascinu, Stefano, Casadei-Gardini, Andrea, and Presa, Jose

Published
2024
Full Text
View/download PDF

3. Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care

Author

Stefanini, Benedetta, Bucci, Laura, Santi, Valentina, Reggidori, Nicola, Lani, Lorenzo, Granito, Alessandro, Pelizzaro, Filippo, Cabibbo, Giuseppe, Di Marco, Mariella, Ghittoni, Giorgia, Campani, Claudia, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Giannini, Edoardo G., Biasini, Elisabetta, Saitta, Carlo, Magalotti, Donatella, Sangiovanni, Angelo, Guarino, Maria, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, Masotto, Alberto, Sacco, Rodolfo, Vidili, Gianpaolo, Mega, Andrea, Azzaroli, Francesco, Nardone, Gerardo, Brandi, Giovanni, Sabbioni, Simone, Vitale, Alessandro, and Trevisani, Franco

Published
2024
Full Text
View/download PDF

4. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments

Author

Cabibbo, Giuseppe, Daniele, Bruno, Borzio, Mauro, Casadei-Gardini, Andrea, Cillo, Umberto, Colli, Agostino, Conforti, Massimiliano, Dadduzio, Vincenzo, Dionisi, Francesco, Farinati, Fabio, Gardini, Ivan, Giannini, Edoardo Giovanni, Golfieri, Rita, Guido, Maria, Mega, Andrea, Cinquini, Michela, Piscaglia, Fabio, Rimassa, Lorenza, Romanini, Laura, Pecorelli, Anna, Sacco, Rodolfo, Scorsetti, Marta, Viganò, Luca, Vitale, Alessandro, and Trevisani, Franco

Published
2024
Full Text
View/download PDF

5. Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments

Author

Cabibbo, Giuseppe, Daniele, Bruno, Borzio, Mauro, Casadei-Gardini, Andrea, Cillo, Umberto, Colli, Agostino, Conforti, Massimiliano, Dadduzio, Vincenzo, Dionisi, Francesco, Farinati, Fabio, Gardini, Ivan, Giannini, Edoardo Giovanni, Golfieri, Rita, Guido, Maria, Mega, Andrea, Minozzi, Silvia, Piscaglia, Fabio, Rimassa, Lorenza, Romanini, Laura, Pecorelli, Anna, Sacco, Rodolfo, Scorsetti, Marta, Viganò, Luca, Vitale, Alessandro, and Trevisani, Franco

Published
2024
Full Text
View/download PDF

6. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis

Author

Scaravaglio, Miki, Nofit, Eugenia, Gallo, Paolo, Galati, Giovanni, Pezzato, Francesco, Rollo, Paolo, D’Ovidio, Erica, Coco, Barbara, Tortora, Annalisa, Fiorini, Cecilia, Venere, Rosanna, Scifo, Gaetano, Cannavò, Mariarita, Feletti, Valentina, Pizzolante, Fabrizio, Giannini, Edoardo Giovanni, Cotugno, Rosa, Fanella, Silvia, Losito, Francesco, Grassi, Giuseppe, Manfredi, Giulia Francesca, Buzzanca, Valerio, Omazzi, Barbara, Casella, Silvia, Zani, Francesca, Ricci, Chiara, Bellia, Valentina, Abenavoli, Ludovico, Morelli, Olivia, Crocè, Lory Saveria, Scivetti, Paolo, Panero, Antonio, Boano, Valentina, Poggi, Guido, Gimignani, Giancarlo, Conforti, Alessandro, Frazzetto, Evelise, Rapisarda, Laura, Demma, Shrin, De Vincentis, Antonio, Ampuero, Javier, Terracciani, Francesca, D’Amato, Daphne, Gerussi, Alessio, Cristoferi, Laura, Cazzagon, Nora, Bonaiuto, Emanuela, Floreani, Annarosa, Calvaruso, Vincenza, Cadamuro, Luca, Degasperi, Elisabetta, Morgando, Anna, Vanni, Ester, Lleo, Ana, Colapietro, Francesca, Alvaro, Domenico, Castellaneta, Antonino, Labanca, Sara, Viganò, Mauro, Distefano, Marco, Pace Palitti, Valeria, De Matthaeis, Nicoletta, Marzioni, Marco, Gómez-Dominguez, Elena, Montero, Jose-Luis, Molina, Esther, Garcia-Buey, Luisa, Casado, Marta, Berenguer, Marina, Conde, Isabel, Simon, Miguel-Angel, Fuentes, Javier, Costa-Moreira, Pedro, Macedo, Guilherme, Jorquera, Francisco, Morillas, Rosa-Maria, Presa, Jose, Sousa, Jose-Manuel, Gomes, Dario, Santos, Luis, Olveira, Antonio, Hernandez-Guerra, Manuel, Aburruza, Leire, Santos, Arsenio, Carvalho, Armando, Uriz, Juan, Gutierrez, Maria-Luisa, Perez, Elia, Chessa, Luchino, Pellicelli, Adriano, Marignani, Massimo, Muratori, Luigi, Niro, Grazia Anna, Brunetto, Maurizia, Ponziani, Francesca Romana, Pompili, Maurizio, Marra, Fabio, Galli, Andrea, Mussetto, Alessandro, Alagna, Giuliano, Simone, Loredana, Bertino, Gaetano, Rosina, Floriano, Cozzolongo, Raffaele, Russello, Maurizio, Baiocchi, Leonardo, Saitta, Carlo, Terreni, Natalia, Zolfino, Teresa, Rigamonti, Cristina, Vigano, Raffaella, Cuccorese, Giuseppe, Pozzoni, Pietro, Pedone, Claudio, Grasso, Simone, Picardi, Antonio, Invernizzi, Pietro, Sacco, Rodolfo, Izzi, Antonio, Fernandez-Rodriguez, Conrado, Vespasiani-Gentilucci, Umberto, and Carbone, Marco

Published
2024
Full Text
View/download PDF

7. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs

Author

Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Benevento, Francesca, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Allegrini, Gloria, Cammà, Calogero, Cabibbo, Giuseppe, Giacchetto, Carmelo Marco, Giuffrida, Paolo, Grassini, Maria Vittoria, Grova, Mauro, Rancatore, Gabriele, Stornello, Caterina, Adotti, Valentina, Cavoli, Tancredi Li, Marra, Fabio, Rosi, Martina, Bevilacqua, Vittoria, Borghi, Alberto, Napoli, Lucia, Conti, Fabio, Frassineti, G.L., Migliano, Maria Teresa, de Matthaeis, Nicoletta, Ponziani, Francesca Romana, Missale, Gabriele, Olivani, Andrea, Capasso, Mario, Cossiga, Valentina, Guarino, Maria, Marina Cela, Ester, Facciorusso, Antonio, Graziosi, Camilla, Lauria, Valentina, Pelecca, Giorgio, Schirripa, Marta, Chegai, Fabrizio, Raso, Armando, Bozzi, Alessio, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Dajti, Elton, Ravaioli, Federico, Plaz Torres, Maria Corina, Pieri, Giulia, Oliveri, Filippo, Ricco, Gabriele, Romagnoli, Veronica, Inno, Alessandro, Marchetti, Fabiana, Coccoli, Pietro, Malerba, Antonio, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Reggidori, Nicola, Bucci, Laura, Santi, Valentina, Stefanini, Benedetta, Lani, Lorenzo, Rampoldi, Davide, Ghittoni, Giorgia, Farinati, Fabio, Masotto, Alberto, Stefanini, Bernardo, Mega, Andrea, Biasini, Elisabetta, Foschi, Francesco Giuseppe, Svegliati-Baroni, Gianluca, Sangiovanni, Angelo, Campani, Claudia, Raimondo, Giovanni, Vidili, Gianpaolo, Gasbarrini, Antonio, Celsa, Ciro, Di Marco, Mariella, Giannini, Edoardo G., Sacco, Rodolfo, Brunetto, Maurizia Rossana, Azzaroli, Francesco, Magalotti, Donatella, Morisco, Filomena, Rapaccini, Gian Ludovico, Nardone, Gerardo, Vitale, Alessandro, and Trevisani, Franco

Published
2023
Full Text
View/download PDF

8. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept

Author

Baccarani, Umberto, Brancaccio, Giuseppina, Cozzolongo, Raffaele, Cucchetti, Alessandro, De Matthaeis, Nicoletta, Di Sandro, Stefano, Famularo, Simone, Finotti, Michele, Foschi, Francesco G, Ghinolfi, Davide, Guarracino, Marco, Gruttadauria, Salvatore, Guarino, Maria, Kostandini, Alba, Lenci, Ilaria, Levi Sandri, Giovanni B, Manzia, Tommaso M, Marasco, Giovanni, Masarone, Mario, Mazzarelli, Chiara, Melandro, Fabio, Miele, Luca, Morisco, Filomena, Nicolini, Daniele, Pagano, Duilio, Pelizzaro, Filippo, Pieri, Giulia, Piscaglia, Fabio, Plaz Torres, Maria Corina, Pravisani, Riccardo, Rendina, Maria, Romano, Fabrizio, Russo, Francesco P, Sacco, Rodolfo, Sangiovanni, Angelo, Sposito, Carlo, Tortora, Raffaella, Tovoli, Francesco, Viganò, Mauro, Violi, Paola, Vitale, Alessandro, Cabibbo, Giuseppe, Iavarone, Massimo, Viganò, Luca, Pinato, David J, Ponziani, Francesca Romana, Lai, Quirino, Casadei-Gardini, Andrea, Celsa, Ciro, Galati, Giovanni, Gambato, Martina, Crocetti, Laura, Renzulli, Matteo, Giannini, Edoardo G, Farinati, Fabio, Trevisani, Franco, and Cillo, Umberto

Published
2023
Full Text
View/download PDF

9. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

Author

Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Benevento, Francesca, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Bertellini, Federica, Farinati, Fabio, Palano, Giorgio, Pelizzaro, Filippo, Penzo, Barbara, Pinto, Elisa, Allegrini, Gloria, Cammà, Calogero, Celsa, Ciro, Giuffrida, Paolo, Stornello, Caterina, Grova, Mauro, Giacchetto, Carmelo Marco, Rancatore, Gabriele, Grassini, Maria Vittoria, Adotti, Valentina, Gitto, Stefano, Marra, Fabio, Rosi, Martina, Bevilacqua, Vittoria, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Napoli, Lucia, Domenicali, Marco, Migliano, Maria Teresa, de Matthaeis, Nicoletta, Ponziani, Francesca Romana, Olivani, Andrea, Missale, Gabriele, Cossiga, Valentina, Capasso, Mario, Morisco, Filomena, Cela, Ester Marina, Facciorusso, Antonio, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Dajti, Elton, Ravaioli, Federico, Oliveri, Filippo, Ricco, Gabriele, Romagnoli, Veronica, Inno, Alessandro, Marchetti, Fabiana, Coccoli, Pietro, Malerba, Antonio, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Giannini, Edoardo G., Pieri, Giulia, Labanca, Sara, Plaz Torres, Maria Corina, Gasbarrini, Antonio, Biasini, Elisabetta, Campani, Claudia, Cazzagon, Nora, Foschi, Francesco Giuseppe, Mega, Andrea, Masotto, Alberto, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Sacco, Rodolfo, Caturelli, Eugenio, Guarino, Maria, Tovoli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Svegliati-Baroni, Gianluca, Magalotti, Donatella, Azzaroli, Francesco, Cabibbo, Giuseppe, Di Marco, Maria, Sangiovanni, Angelo, and Trevisani, Franco

Published
2022
Full Text
View/download PDF

11. Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib.

Author

Stefanini, Bernardo, Ielasi, Luca, Casadei-Gardini, Andrea, Piscopo, Michele, Tortora, Raffaella, Lani, Lorenzo, Pressiani, Tiziana, Sansone, Vito, Sacco, Rodolfo, Magini, Giulia, Renzulli, Matteo, Foschi, Francesco Giuseppe, Piscaglia, Fabio, Tovoli, Francesco, and Granito, Alessandro

Subjects
PROPENSITY score matching, HEPATOCELLULAR carcinoma, LIVER failure, OVERALL survival, SORAFENIB
Abstract

Background: Transarterial chemoembolisation (TACE) and radioembolisation (TARE) can lead to the deterioration of liver function, especially in cases of a high tumour burden, potentially lessening the benefits of subsequent systemic treatments. We aimed to verify whether a high number of previous transarterial treatments modified the outcomes of patients who received sorafenib as a frontline systemic treatment. Methods: A retrospective analysis of a large multicenter dataset containing prospectively collected data of sorafenib-treated patients was conducted. Results: Data from 696 patients were analysed, with 139 patients having received >two transarterial procedures before starting sorafenib. A propensity score matched 139 identified pairs of patients. Having received >two locoregional treatments was independently associated with a shorter survival (hazard ratio 1.325, 95% confidence interval 1.018–1.725, p = 0.039). This pattern was confirmed amongst responders to sorafenib, but not in progressors. A trend toward a higher rate of the permanent discontinuation of sorafenib due to liver failure (18.7 vs. 10.8%, p = 0.089) and a lower rate of eligibility for second-line treatments (24.5 vs. 17.3%, p = 0.184) was observed in patients who had received >two transarterial procedures. Conclusions: Repeated endovascular treatments negatively impacted the survival of HCC patients, especially sorafenib-responders. An early switch to systemic therapies should be considered in cases that are unlikely to respond. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.

Author

Marasco, Giovanni, Colecchia, Antonio, Bacchi Reggiani, Maria Letizia, Celsa, Ciro, Farinati, Fabio, Giannini, Edoardo Giovanni, Benevento, Francesca, Rapaccini, Gian Ludovico, Caturelli, Eugenio, Di Marco, Mariella, Biasini, Elisabetta, Marra, Fabio, Morisco, Filomena, Foschi, Francesco Giuseppe, Zoli, Marco, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Masotto, Alberto, Sacco, Rodolfo, Raimondo, Giovanni, Azzaroli, Francesco, Mega, Andrea, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Dajti, Elton, Ravaioli, Federico, Avanzato, Francesca, Festi, Davide, and Trevisani, Franco

Published
2021
Full Text
View/download PDF

15. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

Author

D’Amato, Daphne, De Vincentis, Antonio, Malinverno, Federica, Viganò, Mauro, Alvaro, Domenico, Pompili, Maurizio, Picciotto, Antonino, Palitti, Valeria Pace, Russello, Maurizio, Storato, Silvia, Pigozzi, Marie Graciella, Calvaruso, Vincenza, De Gasperi, Elisabetta, Lleo, Ana, Castellaneta, Antonino, Pellicelli, Adriano, Cazzagon, Nora, Floreani, Annarosa, Muratori, Luigi, Fagiuoli, Stefano, Niro, Grazia Anna, Feletti, Valentina, Cozzolongo, Raffaele, Terreni, Natalia, Marzioni, Marco, Pellicano, Rinaldo, Pozzoni, Pietro, Baiocchi, Leonardo, Chessa, Luchino, Rosina, Floriano, Bertino, Gaetano, Vinci, Maria, Morgando, Anna, Vanni, Ester, Scifo, Gaetano, Sacco, Rodolfo, D’Antò, Maria, Bellia, Valentina, Boldizzoni, Roberto, Casella, Silvia, Omazzi, Barbara, Poggi, Guido, Cristoferi, Laura, Gerussi, Alessio, Ronca, Vincenzo, Venere, Rosanna, Ponziani, Francesca, Cannavò, Maria, Mussetto, Alessandro, Fontana, Rosanna, Losito, Francesco, Frazzetto, Evelise, Distefano, Marco, Colapietro, Francesca, Labanca, Sara, Marconi, Giulia, Grassi, Giuseppe, Galati, Giovanni, O’Donnell, Sarah Elizabeth, Mancuso, Clara, Mulinacci, Giacomo, Palermo, Andrea, Claar, Ernesto, Izzi, Antonio, Picardi, Antonio, Invernizzi, Pietro, Carbone, Marco, and Vespasiani-Gentilucci, Umberto

Published
2021
Full Text
View/download PDF

16. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis

Author

Vitale, Alessandro, Russo, Francesco Paolo, Cillo, Umberto, Burra, Patrizia, Mescoli, Claudia, Gambato, Martina, Sessa, Anna, Cabibbo, Giuseppe, Viganò, Mauro, Galati, Giovanni, Villa, Erica, Iavarone, Massimo, Brancaccio, Giuseppina, Rendina, Maria, Lupo, Luigi G., Losito, Francesco, Fucilli, Fabio, Persico, Marcello, D’Ambrosio, Roberta, Sangiovanni, Angelo, Cucchetti, Alessandro, Trevisani e Matteo Renzulli, Franco, Miele, Luca, Grieco, Antonio, Lodovico Rapaccini, Gian, Pompili, Maurizio, Gasbarrini, Antonio, Battista Levi Sandri, Giovanni, Melandro, Fabio, Rossi, Massimo, Lenci, Ilaria, Manzia, Tommaso Maria, Tortora, Raffaella, Di Costanzo, Giovan Giuseppe, Sacco, Rodolfo, Ghinolfi, Davide, Rreka, Erion, Carrai, Paola, Simonetti, Natalia, Sposito, Carlo, Bhoori, Sherrie, di Sandro, Stefano, Foschi, Francesco Giuseppe, Casadei Gardini, Andrea, Nicolini, Daniele, Mazzocato, Susanna, Kostandini, Alba, Violi, Paola, Baccarani, Umberto, Pravisani, Riccardo, Vincenzi, Valter, Guarino, Maria, Viganò, Luca, Ponziani, Francesca Romana, Giannini, Edoardo Giovanni, Lai, Quirino, and Morisco, Filomena

Published
2018
Full Text
View/download PDF

19. Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy.

Author

Ielasi, Luca, Stefanini, Bernardo, Conti, Fabio, Tonnini, Matteo, Tortora, Raffaella, Magini, Giulia, Sacco, Rodolfo, Pressiani, Tiziana, Trevisani, Franco, Foschi, Francesco Giuseppe, Piscaglia, Fabio, Granito, Alessandro, and Tovoli, Francesco

Subjects
LIVER, COMPARATIVE studies, OVERALL survival, CLASSIFICATION, ALPHA fetoproteins, HEPATOCELLULAR carcinoma
Abstract

Background: Intermediate-stage hepatocellular carcinoma (BCLC B HCC) occurs in a heterogeneous group of patients and can be addressed with a wide spectrum of treatments. Consequently, survival significantly varies among patients. In recent years, several subclassification systems have been proposed to stratify patients' prognosis. We analyzed and compared these systems (Bolondi, Yamakado, Kinki, Wang, Lee, and Kim criteria) in patients undergoing systemic therapy. Methods: We considered 171 patients with BCLC B HCC treated with sorafenib as first-line systemic therapy in six Italian centers from 2010 to 2021 and retrospectively applied the criteria of six different subclassification systems. Results: Except for the Yamakado criteria, all the subclassification systems showed a statistically significant correlation to overall survival (OS). In the postestimation analysis, the Bolondi criteria (OS of subgroups 22.5, 11.9, and 6.6 mo, respectively; C-index 0.586; AIC 1338; BIC 1344) and the Wang criteria (OS of subgroups 20.6, 11.9, and 7.0, respectively; C-index 0.607; AIC 1337; BIC 1344) presented the best accuracy. Further analyses of these two subclassification systems implemented with the prognostic factor of alpha-fetoprotein (AFP) > 400 ng/mL have shown an increase in accuracy for both systems (C-index 0.599 and 0.624, respectively). Conclusions: Intermediate-stage subclassification systems maintain their predictive value also in the setting of systemic therapy. The Bolondi and Wang criteria showed the highest accuracy. AFP > 400 ng/mL enhances the performance of these systems. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group

Author

Vitale, Alessandro, Lai, Quirino, Farinati, Fabio, Bucci, Laura, Giannini, Edoardo G., Napoli, Lucia, Ciccarese, Francesca, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Virdone, Roberto, Marra, Fabio, Felder, Martina, Morisco, Filomena, Benvegnù, Luisa, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Colecchia, Antonio, Bernardi, Mauro, Trevisani, Franco, Pawlik, Timothy M., and On behalf of the Italian Liver Cancer (ITA.LI.CA) group

Published
2018
Full Text
View/download PDF

23. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study

Author

Vitale, Alessandro, Burra, Patrizia, Frigo, Anna Chiara, Trevisani, Franco, Farinati, Fabio, Spolverato, Gaya, Volk, Michael, Giannini, Edoardo G., Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Gasbarrini, Antonio, Sacco, Rodolfo, Foschi, Francesco Giuseppe, Missale, Gabriele, Morisco, Filomena, Svegliati Baroni, Gianluca, Virdone, Roberto, and Cillo, Umberto

Published
2015
Full Text
View/download PDF

25. Cholangiocarcinoma in the Era of Immunotherapy.

Author

Manthopoulou, Eleni, Ramai, Daryl, Dhar, Jahnvi, Samanta, Jayanta, Ioannou, Alexandros, Lusina, Ekaterina, Sacco, Rodolfo, and Facciorusso, Antonio

Subjects
CHOLANGIOCARCINOMA, IMMUNE checkpoint inhibitors, GASTROINTESTINAL cancer, IMMUNOTHERAPY, CANCER vaccines
Abstract

Cholangiocarcinoma (CCA) is a rare malignancy of the gastrointestinal tract, with aggressive behavior, and portends a poor prognosis. Traditionally, it is classified according to its site of involvement as intrahepatic, perihilar, and distal cholangiocarcinoma. A host of genetic and epigenetic factors have been involved in its pathogenesis. Chemotherapy has remained the standard first-line treatment over the last decade, with a disappointing median overall survival of 11 months for locally advanced and metastatic CCA. The advent of immunotherapy has revolutionized the treatment of many pancreaticobiliary malignancies, offering durable responses with a safe therapeutic profile. To date, there have been no significant advances in the management of CCA. Novel immunotherapeutic methods, such as cancer vaccines, adoptive cell therapy, and combinations of immune checkpoint inhibitors with other agents, are currently under investigation and may improve prognosis with overall survival. Efforts to find robust biomarkers for response to treatment along with multiple clinical trials are also ongoing in this regard. In this review, we present an overview of the current advances and the future perspectives of immunotherapy in the management of CCA. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. THU-093 Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid

Author

Vincentis, Antonio De, Terracciani, Francesca, D'Amato, Daphne, Scaravaglio, Miki, Invernizzi, Pietro, Vanni, Ester, Campion, Daniela, Floreani, Annarosa, Cazzagon, Nora, Alvaro, Domenico, Venere, Rosanna, Giannini, Edoardo, Labanca, Sara, Lleo, Ana, Colapietro, Francesca, Degasperi, Elisabetta, Viganò, Mauro, Pesatori, Eugenia Vittoria, Fagiuoli, Stefano, Marzioni, Marco, Buzzanca, Valerio, Viganò, Raffaella, D'Amico, Federico, Galli, Andrea, Curto, Armando, Marra, Fabio, Begini, Paola, Baiocchi, Leonardo, Carnì, Paola, Muratori, Luigi, Coco, Barbara, Brunetto, Maurizia, Pizzolante, Fabrizio, Matthaeis, Nicoletta De, Falbo, Elisabetta, Surace, Lorenzo, Mattalia, Alberto, Ieluzzi, Donatella, Salomone, Federico, Monache, Guido Delle, Tatonetti, Riccardo, Cavalli, Ilaria, Cossiga, Valentina, Morisco, Filomena, Valiani, Vincenzo, Gatti, Pietro, Boccaccio, Vincenzo, Angrisani, Debora, Vettori, Giovanni, Cuffari, Biagio, Moretti, Alessandra, Rocco, Alba, Nardone, Gerardo, Scivetti, Paolo, Costanzo, Martina, Boano, Valentina, Manfredi, Giulia Francesca, Simone, Loredana, Palitti, Valeria Pace, Russello, Maurizio, Cannavò, Maria Rita, Frazzetto, Evelise, Bertino, Gaetano, Distefano, Marco, Izzi, Antonio, Cerini, Federica, Chessa, Luchino, Miglianti, Michela, Feletti, Valentina, Mussetto, Alessandro, Cozzolongo, Raffaele, Losito, Francesco, Niro, Grazia Anna, Cotugno, Rosa, Sacco, Rodolfo, Ricci, Chiara, Poisa, Paolo, Cadamuro, Luca, Castellaneta, Antonino, Squeo, Francesco, Terreni, Natalia, Bina, Niccolò, Pozzoni, Pietro, Casella, Silvia, Zani, Francesca, Morelli, Olivia, Cuccorese, Giuseppe, Saitta, Carlo, Zolfino, Teresa, Rigamonti, Cristina, Calvaruso, Vincenza, Carbone, Marco, and Vespasiani-Gentilucci, Umberto

Published
2024
Full Text
View/download PDF

31. TOP-085 Final results from the italian real-world experience on lusutrombopag treatment in cirrhotic patients with severe thrombocytopenia: insights from the reality study

Author

Gallo, Paolo, De Vincentis, Antonio, Pace Palitti, Valeria, Russello, Maurizio, Vignone, Anthony, Alvaro, Domenico, Tortora, Raffaella, biolato, marco, Pompili, Maurizio, Calvaruso, Vincenza, Veneziano, Marzia, Tizzani, Marco, Frigo, Francesco, Caneglias, Alessandro, Marcantonio, Gesualdo, Marzano, Alfredo, Rosato, Valerio, Claar, Ernesto, Villani, Rosanna, Izzi, Antonio, Cozzolongo, Raffaele, Airoldi, Aldo, Mazzarelli, Chiara, Distefano, Marco, Iegri, Claudia, Fagiuoli, Stefano, Messina, Vincenzo, Ragone, Enrico, Sacco, Rodolfo, Cacciatore, Pierluigi, Masutti, Flora, Saveria Crocè, Lory, Moretti, Alessandra, Terracciani, Francesca, Falcomata, Andrea, Di Pasquale, Giulia, Flagiello, Valentina, Picardi, Antonio, and Vespasiani-Gentilucci, Umberto

Published
2024
Full Text
View/download PDF

32. LBP-038 Expanding knowledge regarding real-world treatment of patients with primary biliary cholangitis with obeticholic acid from the Italian RECAPITULATE cohort

Author

Terracciani, Francesca, De Vincentis, Antonio, D'Amato, Daphne, Scaravaglio, Miki, Invernizzi, Pietro, Vanni, Ester, Campion, Daniela, Floreani, Annarosa, Cazzagon, Nora, Alvaro, Domenico, Venere, Rosanna, Giannini, Edoardo, Labanca, Sara, Lleo, Ana, Colapietro, Francesca, Degasperi, Elisabetta, Vigano, Mauro, Pesatori, Eugenia Vittoria, Fagiuoli, Stefano, Marzioni, Marco, Buzzanca, Valerio, Vigano, Raffaella, D'Amico, Federico, Galli, Andrea, Curto, Armando, Marra, Fabio, Begini, Paola, Baiocchi, Leonardo, Carni, Paola, Muratori, Luigi, Coco, Barbara, Brunetto, Maurizia, Pizzolante, Fabrizio, De Matthaeis, Nicoletta, Falbo, Elisabetta, Surace, Lorenzo, Mattalia, Alberto, Ieluzzi, Donatella, Salomone, Federico, Monache, Guido Delle, Tatonetti, Riccardo, Cavalli, Ilaria, Cossiga, Valentina, Morisco, Filomena, Valiani, Vincenzo, Gatti, Pietro, Boccaccio, Vincenzo, Angrisani, Debora, Vettori, Giovanni, Cuffari, Biagio, Moretti, Alessandra, Nardone, Gerardo, Rocco, Alba, Scivetti, Paolo, Costanzo, Martina, Boano, Valentina, Manfredi, Giulia Francesca, Simone, Loredana, Palitti, Valeria Pace, Russello, Maurizio, Cannavo, Maria Rita, Frazzetto, Evelise, Bertino, Gaetano, Distefano, Marco, Izzi, Antonio, Cerini, Federica, Chessa, Luchino, Miglianti, Michela, Feletti, Valentina, Mussetto, Alessandro, Cozzolongo, Raffaele, Losito, Francesco, Niro, Grazia Anna, Cotugno, Rosa, Sacco, Rodolfo, Ricci, Chiara, Poisa, Paolo, Cadamuro, Luca, Castellaneta, Antonino, Squeo, Francesco, Terreni, Natalia, Bina, Niccolo, Pozzoni, Pietro, Casella, Silvia, Zani, Francesca, Morelli, Olivia, Cuccorese, Giuseppe, Saitta, Carlo, Zolfino, Teresa, Rigamonti, Cristina, Calvaruso, Vincenza, Carbone, Marco, and Vespasiani-Gentilucci, Umberto

Published
2024
Full Text
View/download PDF

33. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma

Author

Pecorelli, Anna, Lenzi, Barbara, Gramenzi, Annagiulia, Garuti, Francesca, Farinati, Fabio, Giannini, Edoardo G., Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Felder, Martina, Morisco, Filomena, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Foschi, Francesco G., Biasini, Elisabetta, Masotto, Alberto, Virdone, Roberto, Bernardi, Mauro, Trevisani, Franco, Bolondi, Luigi, Biselli, Maurizio, Bucci, Laura, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Magalotti, Donatella, Serra, Carla, Venerandi, Laura, Giacomin, Anna, Maddalo, Gemma, Pozzan, Caterina, Vani, Veronica, Poggio, Paolo Del, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Bosco, Giulia, Roselli, Paola, DellʼIsola, Serena, Ialungo, Anna Maria, Bruzzone, Linda, Picciotto, Antonino, Marenco, Simona, Risso, Domenico, Sammito, Giorgio, Savarino, Vincenzo, Cammà, Calogero, Maida, Marcello, Costantino, Andrea, Barcellona, Maria Rosa, Affronti, Andrea, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, Cappa, Federica Mirici, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Missale, Gabriele, Porro, Emanuela, Guarino, Maria, Gemini, Stefano, and Schiadà, Laura

Published
2017
Full Text
View/download PDF

34. The evolutionary scenario of hepatocellular carcinoma in Italy: an update

Author

Bucci, Laura, Garuti, Francesca, Lenzi, Barbara, Pecorelli, Anna, Farinati, Fabio, Giannini, Edoardo G., Granito, Alessandro, Ciccarese, Francesca, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cammà, Calogero, Virdone, Roberto, Marra, Fabio, Felder, Martina, Morisco, Filomena, Benvegnù, Luisa, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Colecchia, Antonio, Bernardi, Mauro, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Napoli, Lucia, Negrini, Giulia, Piscaglia, Fabio, Serra, Carla, Tovoli, Francesco, Marafatto, Filippo, Murer, Francesca, Peserico, Giulia, Pozzan, Caterina, Vanin, Veronica, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Poggio, Paolo Del, Olmi, Stefano, de Matthaeis, Nicoletta, Balsamo, Claudia, Vavassori, Elena, Roselli, Paola, Dell’Isola, Serena, Ialungo, Anna Maria, Rastrelli, Elena, Barcellona, Maria Rosa, Cabibbo, Giuseppe, Costantino, Andrea, Maida, Marcello, Affronti, Andrea, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, Dall’Aglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Porro, Emanuela, Guarino, Maria, Gemini, Stefano, Schiadà, Laura, Chiaramonte, Maria, Marchetti, Fabiana, Valerio, Matteo, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Coccoli, Piero, Zamparelli, Marco Sanduzzi, Aburas, Sami, and Inghilesi, Andrea Lorenzo

Published
2017
Full Text
View/download PDF

35. Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma.

Author

Ielasi, Luca, Tovoli, Francesco, Tonnini, Matteo, Stefanini, Bernardo, Tortora, Raffaella, Magini, Giulia, Sacco, Rodolfo, Pressiani, Tiziana, Trevisani, Franco, Garajová, Ingrid, Piscaglia, Fabio, and Granito, Alessandro

Subjects
COMPARATIVE studies, SORAFENIB, DESCRIPTIVE statistics, PROGRESSION-free survival, RADIOTHERAPY, HEPATOCELLULAR carcinoma, PALLIATIVE treatment
Abstract

Simple Summary: Several retrospective studies tried to assess the prognostic role of different sites of metastases in patients with advanced HCC, but results are often contradictory. These studies also presented results based on population samples with several confounding factors. Although the therapeutic scenario is moving towards immunotherapy, a better knowledge of a different metastatic site response rate to sorafenib is needed, also considering the potential future advent of combination therapies with immune checkpoint and tyrosine-kinase inhibitors. We tried to perform a large-scale multicentric study by enrolling metastatic HCC patients treated with sorafenib as front-line therapy. A low rate of concomitant locoregional treatments during sorafenib in our population study allowed us to focus on the actual response of different sites of metastases to systemic treatment with sorafenib, showing that lymph nodes and lung metastases have worse prognosis. Extrahepatic spread is a well-known negative prognostic factor in patients with advanced hepatocellular carcinoma (HCC). The prognostic role of different metastatic sites and their response rate to systemic treatment is still being debated. We considered 237 metastatic HCC patients treated with sorafenib as first-line therapy in five different Italian centers from 2010 to 2020. The most common metastatic sites were lymph nodes, lungs, bone and adrenal glands. In survival analysis, the presence of dissemination to lymph nodes (OS 7.1 vs. 10.2 months; p = 0.007) and lungs (OS 5.9 vs. 10.2 months; p < 0.001) were significantly related to worse survival rates compared with all other sites. In the subgroup analysis of patients with only a single metastatic site, this prognostic effect remained statistically significant. Palliative radiation therapy on bone metastases significantly prolonged survival in this cohort of patients (OS 19.4 vs. 6.5 months; p < 0.001). Furthermore, patients with lymph node and lung metastases had worse disease control rates (39.4% and 30.5%, respectively) and shorter radiological progression-free survival (3.4 and 3.1 months, respectively). In conclusion, some sites of an extrahepatic spread of HCC have a prognostic impact on survival in patients treated with sorafenib; in particular, lymph nodes and lung metastases have worse prognosis and treatment response rate. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study

Author

Bargellini, Irene, Sacco, Rodolfo, Bozzi, Elena, Bertini, Marco, Ginanni, Barbara, Romano, Antonio, Cicorelli, Antonio, Tumino, Emanuele, Federici, Graziana, Cioni, Roberto, Metrangolo, Salvatore, Bertoni, Michele, Bresci, Giampaolo, Parisi, Giuseppe, Altomare, Emanuele, Capria, Alfonso, and Bartolozzi, Carlo

Published
2012
Full Text
View/download PDF

39. Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis.

Author

Sacco, Rodolfo, Ramai, Daryl, Tortora, Raffaella, di Costanzo, Giovan Giuseppe, Burlone, Michela Emma, Pirisi, Mario, Federico, Piera, Daniele, Bruno, Silletta, Marianna, Gallo, Paolo, Cocuzza, Caterina, Russello, Maurizio, Cabibbo, Giuseppe, Rancatore, Gabriele, Cesario, Silvia, Masi, Gianluca, Marzi, Luca, Mega, Andrea, Granito, Alessandro, and Pieri, Giulia

Subjects
*THERAPEUTIC use of monoclonal antibodies, *RESEARCH, *CONFIDENCE intervals, *LOG-rank test, *INFLAMMATION, *IMMUNOSUPPRESSION, *CANCER patients, *KAPLAN-Meier estimator, *SURVIVAL analysis (Biometry), *DESCRIPTIVE statistics, *FACTOR analysis, *PROGRESSION-free survival, *ODDS ratio, *HEPATOCELLULAR carcinoma, *OVERALL survival
Abstract

Simple Summary: Hepatocellular carcinoma is the fifth most common cancer worldwide. For patients with advanced hepatocellular carcinoma, therapeutic options are limited. Lenvatinib has proven to be an effective option for treating advanced diseases. For patients treated with lenvatinib, our study showed that the etiology of liver disease plays a significant role in overall survival. Patients whose liver disease was driven by nonviral etiologies showed longer survival than viral etiologies. These results are important for clinical decision-making between patients and clinicians. Background: Whether the etiology of underlying liver disease represents a prognostic factor in patients with hepatocellular carcinoma (HCC) treated with lenvatinib is still a matter of debate. This study investigates whether the viral etiology of HCC plays a prognostic role in overall survival (OS). Methods: Data derived from a multicenter series of 313 HCC patients treated with lenvatinib between 2019 and 2022 were analyzed. Actuarial survival estimates were computed using the Kaplan–Meier method and compared with the log-rank test. We performed an event-based counterfactual mediation analysis to estimate direct (chronic inflammation and immunosuppression), indirect (tobacco smoking, alcohol use, illicit drug abuse with injections), and the total effect of viral etiology on OS. Results were expressed as hazard ratio (HR) and 95% CI. Results: Median OS was 21 months (95% CI: 20–23) in the group with other etiologies and 15 months (14–16) in the group with viral etiology (p < 0.0001). The total effect of viral etiology was associated with OS (HR 2.76, 1.32–5.21), and it was mainly explained by the pure direct effect of viral etiology (HR 2.74, 1.15–4.45). By contrast, its total indirect effect was not associated with poorer survival (HR 1.05, 0.82–2.13). These results were confirmed when considering tobacco, alcohol consumption, or injection drug abuse as potential mediators. Median progression-free survival was 9 months (8–10) in patients with other etiologies and 6 months (5–7) in patients with viral etiology (p < 0.0001). No difference in terms of adverse event rate was observed between the two groups. Conclusions: Patients affected by HCC with nonviral etiology treated with lenvatinib exhibit longer survival than those with viral etiology. This finding may have relevance in the treatment decision-making process. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.

Author

Vitale, Alessandro, Svegliati-Baroni, Gianluca, Ortolani, Alessio, Cucco, Monica, Riva, Giulio V. Dalla, Giannini, Edoardo G., Piscaglia, Fabio, Rapaccini, Gianludovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Foschi, Francesco Giuseppe, Missale, Gabriele, and Masotto, Alberto

Subjects
HEPATOCELLULAR carcinoma, FATTY liver, MEDICAL personnel, HEPATITIS C, MEDICAL sciences, MEDICAL specialties & specialists, NON-alcoholic fatty liver disease
Published
2023
Full Text
View/download PDF

41. Correction: Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma

Author

Giannini, Edoardo G., Moscatelli, Alessandro, Pellegatta, Gaia, Vitale, Alessandro, Farinati, Fabio, Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Sacco, Rodolfo, Morisco, Filomena, Missale, Gabriele, Foschi, Francesco Giuseppe, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Virdone, Roberto, Masotto, Alberto, Trevisani, Franco, and and the Italian Liver Cancer (ITA.LI.CA) Group

Published
2018
Full Text
View/download PDF

42. Utility-Based Criteria for Selecting Patients With Hepatocellular Carcinoma for Liver Transplantation: A Multicenter Cohort Study Using the Alpha-Fetoprotein Model as a Survival Predictor

Author

Vitale, Alessandro, Farinati, Fabio, Burra, Patrizia, Trevisani, Franco, Giannini, Edoardo G., Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Sacco, Rodolfo, Morisco, Filomena, Missale, Gabriele, Foschi, Francesco Giuseppe, Gasbarrini, Antonio, Svegliati Baroni, Gianluca, Virdone, Roberto, Chiaramonte, Maria, Spolverato, Gaya, and Cillo, Umberto

Published
2015
Full Text
View/download PDF

47. Organizing a Scholarly Congress.

Author

Sacco, Rodolfo

Abstract

In a tongue-in-cheek fashion, practical and creative suggestions for planning and carrying out a conference on legal scholarship are discussed, including topic selection, financing, choice of speakers, working sessions, logistical planning, and publication of the proceedings. (MSE)

Published
1990

50. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors.

Author

Stefanini, Benedetta, Bucci, Laura, Santi, Valentina, Reggidori, Nicola, Rampoldi, Davide, Lani, Lorenzo, Granito, Alessandro, Sangiovanni, Angelo, Cabibbo, Giuseppe, Farinati, Fabio, Campani, Claudia, Foschi, Francesco Giuseppe, Svegliati-Baroni, Gianluca, Raimondo, Giovanni, Gasbarrini, Antonio, Mega, Andrea, Biasini, Elisabetta, Sacco, Rodolfo, Morisco, Filomena, and Caturelli, Eugenio

Abstract

The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular carcinoma not amenable to locoregional treatments, becoming the standard of care of systemic therapy. This study aimed at assessing real-world feasibility of atezolizumab-bevacizumab in patients treated with tyrosine-kinase inhibitors. Among 1447 patients treated with tyrosine-kinase inhibitors from January 2010 to December 2020, we assessed the percentage of those potentially eligible to atezolizumab-bevacizumab (according to IMbrave-150 trial criteria), and the overall survival of eligible and non-eligible patients. 422 (29%) patients were qualified for atezolizumab-bevacizumab therapy. The main exclusion causes were Child-Pugh class and Performance Status. Adopting the more permissive inclusion criteria of SHARP trial, 535 patients became eligible. The median overall survival of tyrosine-kinase inhibitors patients was 14.9 months, longer in eligible patients than in their counterpart due to better baseline liver function and oncological features. Real-world data indicate that less than one-third of hepatocellular carcinoma patients treated with tyrosine-kinase inhibitors are potentially eligible to atezolizumab-bevacizumab according to the registration trial criteria. These patients have a longer survival than the non-eligible ones. If the selection criteria of atezolizumab-bevacizumab trial are maintained in clinical practice, tyrosine-kinase inhibitors will remain the most used systemic therapy for hepatocellular carcinoma patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results